Use of Truvada for PrEP Tied to Decrease in New HIV Infections
Use of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) for HIV prevention was associated with a significant decline in new diagnoses across the United States.
Use of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) for HIV prevention was associated with a significant decline in new diagnoses across the United States, according to new data presented at the International AIDS Conference.
Gilead Sciences announced the new results based on a retrospective nationwide analysis on the impact of once-daily oral Truvada for pre-exposure prophylaxis (PrEP) use.
Truvada for PrEP was approved by the FDA in 2012 to be used in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg.
For the analysis, researchers used state-level data based on National HIV Surveillance System and national pharmacy data on HIV diagnoses and prevalence of use of Truvada for PrEP from 2012 to 2016.
Click to continue reading on Specialty Pharmacy Times.
